SUBLOCADE
Drug
Indivior Inc.
Total Payments
$32.1M
Transactions
70,941
Doctors
17,577
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $4.5M | 19,370 | 7,680 |
| 2023 | $13.6M | 10,636 | 4,846 |
| 2022 | $5.4M | 7,375 | 3,619 |
| 2021 | $372,041 | 5,716 | 3,119 |
| 2020 | $797,997 | 3,253 | 1,675 |
| 2019 | $1.0M | 9,612 | 3,417 |
| 2018 | $1.9M | 13,291 | 4,742 |
| 2017 | $4.6M | 1,688 | 69 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $27.4M | 6,158 | 85.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.1M | 1,657 | 6.4% |
| Food and Beverage | $1.5M | 60,117 | 4.8% |
| Consulting Fee | $553,763 | 131 | 1.7% |
| Travel and Lodging | $416,337 | 2,233 | 1.3% |
| Honoraria | $102,855 | 73 | 0.3% |
| Space rental or facility fees (teaching hospital only) | $9,550 | 7 | 0.0% |
| Education | $2,475 | 564 | 0.0% |
| Entertainment | $55.12 | 1 | 0.0% |
Payments by Type
Research
$27.4M
6,158 transactions
General
$4.7M
64,783 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use | Indivior Inc. | $14.8M | 0 |
| A Single-Dose Study to Evaluate the Relative Bioavailability, Safety, and Tolerability of SUBLOCADE at Alternative Injection Locations in Adults | Indivior Inc. | $3.2M | 0 |
| An Open-Label, Long-Term Safety and Tolerability Study of Depot Buprenorphine RBP-6000 in Treatment-Seeking Subjects With Opioid Use Disorder | Indivior Inc. | $3.1M | 0 |
| A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE | Indivior Inc. | $2.1M | 0 |
| An Open-Label, Depot Buprenorphine RBP-6000 Treatment Extension Study in Subjects With Opioid Use Disorder | Indivior Inc. | $1.3M | 23 |
| A SINGLE-DOSE STUDY TO EVALUATE THE RELATIVE BIOAVAILABILITY, SAFETY, AND TOLERABILITY OF SUBLOCADE AT ALTERNATIVE INJECTION LOCATIONS IN ADULTS | Indivior Inc. | $1.0M | 0 |
| A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) | Indivior Inc. | $711,478 | 0 |
| An Open-label, Rapid Initiation Study for Extended-Release Buprenorphine Subcutaneous Injection (SUBLOCADE) | Indivior Inc. | $234,175 | 0 |
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess the Efficacy, Safety, and Tolerability of Multiple Subcutaneous Injections of Depot Buprenorphine RBP-6000 100 mg and 300 mg Over 24 Weeks in Treatment-Seeking Subjects With Opioid Use Disorder | Indivior Inc. | $149,692 | 12 |
| A Phase IV Longitudinal Study of SUBLOCADE (SUBUTEX Prolonged Release) Clinical Outcomes in Adults With Opioid Use Disorder (Opioid Dependence) | Indivior Inc. | $106,667 | 0 |
| AN OPEN-LABEL, LONG-TERM SAFETY AND TOLERABILITY STUDY OF DEPOT BUPRENORPHINE RBP-6000 IN TREATMENT-SEEKING SUBJECTS WITH OPIOID USE DISORDER | Indivior Inc. | $102,996 | 0 |
| Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults | Indivior Inc. | $87,161 | 0 |
| AN OPEN-LABEL, LONG-TERM SAFETY AND TOLERABILITY STUDY OF DEPOT BUPRENORPHINE (RBP-6000) IN TREATMENT-SEEKING SUBJECTS WITH OPIOID USE DISORDER | Indivior Inc. | $82,059 | 0 |
| EVALUATION OF LONG-TERM BUPRENORPHINE PLASMA EXPOSURE IN SUBJECTS WHO RECEIVED AT LEAST 2 SUBCUTANEOUS INJECTIONS OF EXTENDED-RELEASE BUPRENORPHINE SUBLOCADE IN PHASE III STUDIES | Indivior Inc. | $67,750 | 0 |
| An Open-label, Treatment Extension Study for the Rapid Initiation of Extended-Release Buprenorphine Subcutaneous Injection (SUBLOCADE) | Indivior Inc. | $66,570 | 0 |
| RAE (REALIZE, ANALYZE, ENGAGE) A DIGITAL BIOMARKER SYSTEM FOR MONITORING CRAVING AMONG INDIVIDUALS IN TREATMENT FOR OPIOID USE DISORDER WITH SUBLOCADE (BUP-XR) | Indivior Inc. | $59,000 | 0 |
| Randomized, Placebo-Controlled Trial of Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2) | Indivior Inc. | $52,753 | 0 |
| A PHASE IV STUDY TO EVALUATE THE SUBLOCADE TREATMENT EXIT STRATEGY | Indivior Inc. | $38,023 | 0 |
| LONG-ACTING BUPRENORPHINE VS. NALTREXONE OPIOID TREATMENTS IN CJS-INVOLVED ADULTS | Indivior Inc. | $33,883 | 0 |
| Virginia Opioid overdose Treatment InitiatiVE | Indivior Inc. | $29,850 | 0 |
Top Doctors Receiving Payments for SUBLOCADE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Oklahoma City, OK | $27.9M | 6,258 |
| , MD | Psychiatry | Los Angeles, CA | $344,185 | 78 |
| , MD | Internal Medicine | Pacific Palisades, CA | $101,238 | 342 |
| , M.D | Addiction Psychiatry | New Orleans, LA | $82,557 | 63 |
| , M.D | Psychosomatic Medicine | Prairie Village, KS | $75,783 | 212 |
| , DMD, DO | General Practice | Hamilton, AL | $63,042 | 84 |
| , MD | Hospice and Palliative Medicine | Shreveport, LA | $55,437 | 167 |
| , D.O | Family Medicine | Lancaster, PA | $54,621 | 126 |
| , M.D | Internal Medicine | Ambler, PA | $54,546 | 102 |
| , MD | Internal Medicine | Vernon Hills, IL | $48,095 | 86 |
| , DO | Addiction Medicine | Monroe, WA | $41,797 | 140 |
| , M.D | Addiction Medicine | Worcester, NY | $39,284 | 141 |
| , MD | Psychiatry | Salem, MA | $38,246 | 105 |
| , M.D | Psychiatry | Tampa, FL | $37,952 | 40 |
| , MD | Internal Medicine | Madison, TN | $35,262 | 89 |
| , D.O | Family Medicine | Mercer Island, WA | $34,801 | 95 |
| , MD | Internal Medicine | Birmingham, AL | $34,190 | 91 |
| David Best | — | Traverse City, MI | $33,045 | 102 |
| , MD | Pain Medicine | Plano, TX | $32,311 | 109 |
| , M.D | Internal Medicine | Asheboro, NC | $31,795 | 87 |
| , MD | Addiction Medicine | Troy, MI | $30,520 | 65 |
| , D.O | Physical Medicine & Rehabilitation | La Jolla, CA | $29,144 | 94 |
| , M.D | Addiction Medicine | Smyrna, GA | $28,830 | 124 |
| , M.D | Addiction Medicine | New York, NY | $28,712 | 10 |
| , MD | Internal Medicine | Burlingame, CA | $28,186 | 136 |
Ad
Manufacturing Companies
- Indivior Inc. $32.1M
- Indivior Canada Ltd $12,275
Product Information
- Type Drug
- Total Payments $32.1M
- Total Doctors 17,577
- Transactions 70,941
About SUBLOCADE
SUBLOCADE is a drug associated with $32.1M in payments to 17,577 healthcare providers, recorded across 70,941 transactions in the CMS Open Payments database. The primary manufacturer is Indivior Inc..
Payment data is available from 2017 to 2024. In 2024, $4.5M was paid across 19,370 transactions to 7,680 doctors.
The most common payment nature for SUBLOCADE is "Unspecified" ($27.4M, 85.4% of total).
SUBLOCADE is associated with 20 research studies, including "A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use" ($14.8M).